Top News Stories November 29 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.

Apple Inc. (AAPL)

Continue reading “Top News Stories November 29 2017”

Celgene Stock Now Oversold After Miss and Stopped REVOLVE Trial

Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.

Celgene stock looks like a good oversold setup. The stock plunged -35% when the news broke that Celgene stopped its phase 3 trial of REVOLVE and lowered guidance for 2020. I think the sell-off that followed is now over.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sarepta Therapeutics In Strong Uptrend From Exondys 51

Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

BeiGene Stock Exploding Large Players Volume On Candle Over Candle

BeiGene stock has large players volume exploding higher. The company reported eye-popping earnings and revenue beats this week.

BeiGene stock has exploding large players volume and the company reported the biggest earnings and revenue beats of any company this week. The beats were the result of the Celgene strategic collaboration.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Top News Stories November 14 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”

Deciphera Pharmaceuticals Quiet Period Ended This Week

Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.

Deciphera Pharmaceuticals' quiet period ended on Tuesday, November 7, 2017. The brokerages that served as underwriters are working on research reports and will likely release those reports and analyst ratings on this company soon. In other words, the pump of this stock should start any week now. Please review this lesson on institutional traders and market makers.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Intercept Pharmaceuticals Rising Large Players Volume

Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.

Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Incyte Corporation Rising Large Players Volume in Ascending Triangle

Incyte Corporation stock has rising large players volume in an Ascending Triangle pattern. The large players volume rising while Incyte has been consolidating is a bullish pattern.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sorrento Therapeutics Inc Bounce Off 61.8 Percent Retracement

Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.